Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. SPY

Go back to Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D
(NASDAQ: ARQT) Delayed: 24.87 -0.27 (1.07%)
Previous Close $25.14    52 Week High $ 
Open $24.95    52 Week Low $ 
Day High $25.15    P/E N/A 
Day Low $24.60    EPS $ 
Volume 2,204,608       

(NASDAQ: ARQT) Delayed: 24.87 -0.27 (1.07%)
Previous Close $25.14    52 Week High $ 
Open $24.95    52 Week Low $ 
Day High $25.15    P/E N/A 
Day Low $24.60    EPS $ 
Volume 2,204,608